Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) – Equities research analysts at Cantor Fitzgerald issued their FY2018 earnings per share (EPS) estimates for Sunesis Pharmaceuticals in a research note issued on Sunday. Cantor Fitzgerald analyst M. Goldstein expects that the biopharmaceutical company will earn ($1.08) per share for the year. Cantor Fitzgerald currently has a “Hold” rating and a $4.00 target price on the stock.

How to Become a New Pot Stock Millionaire

Several other equities research analysts have also recently weighed in on the stock. Wells Fargo & Co cut shares of Sunesis Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $2.70 to $2.00 in a research report on Tuesday, December 5th. ValuEngine cut shares of Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Oppenheimer initiated coverage on shares of Sunesis Pharmaceuticals in a research report on Thursday, December 14th. They issued a “buy” rating and a $7.00 price objective for the company. Zacks Investment Research cut shares of Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, February 15th. Finally, UBS Group initiated coverage on shares of Sunesis Pharmaceuticals in a research report on Monday, November 20th. They issued an “outperform” rating for the company. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $4.00.

Shares of Sunesis Pharmaceuticals (NASDAQ SNSS) opened at $4.24 on Wednesday. The company has a debt-to-equity ratio of -0.34, a current ratio of 1.84 and a quick ratio of 1.84. The firm has a market cap of $139.63, a PE ratio of -2.79 and a beta of 1.39. Sunesis Pharmaceuticals has a 1 year low of $1.82 and a 1 year high of $7.69.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.08.

Several large investors have recently modified their holdings of SNSS. Wells Fargo & Company MN grew its position in shares of Sunesis Pharmaceuticals by 77.4% during the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 18,254 shares during the period. Geode Capital Management LLC grew its position in shares of Sunesis Pharmaceuticals by 105.2% during the 4th quarter. Geode Capital Management LLC now owns 125,489 shares of the biopharmaceutical company’s stock worth $463,000 after buying an additional 64,343 shares during the period. BlackRock Inc. grew its position in shares of Sunesis Pharmaceuticals by 9.5% during the 4th quarter. BlackRock Inc. now owns 130,573 shares of the biopharmaceutical company’s stock worth $482,000 after buying an additional 11,351 shares during the period. Vatera Holdings LLC acquired a new stake in shares of Sunesis Pharmaceuticals during the 4th quarter worth approximately $673,000. Finally, Vanguard Group Inc. grew its position in shares of Sunesis Pharmaceuticals by 4.1% during the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock worth $1,635,000 after buying an additional 23,819 shares during the period. Institutional investors own 53.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.dailypolitical.com/2018/03/14/research-analysts-issue-forecasts-for-sunesis-pharmaceuticals-inc-s-fy2018-earnings-snss.html.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.